Nivolumab combined with AVD demonstrated superior progression-free survival compared with brentuximab vedotin with AVD in advanced classical Hodgkin lymphoma (cHL). The SWOG S1826 trial showed a ...

The team behind a government plan to protect Bermuda’s waters that has drawn opposition from the fishing community outlined the importance of the measures in a public lecture. Future-proofing ...

Dysregulated complement pathways are linked to progression from iAMD to advanced AMD, including NVAMD and GA. Higher systemic levels of C4, C4b, and a reduction in C3 are associated with increased ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

The complement system is a key component of the innate immune system. In antiacetylcholine receptor (AChR) antibody-positive (Ab+) generalized myasthenia gravis (MG), complement activation has long ...

Any project, supported or not by a committee, that is currently being worked on or is considered active, and will have an end date. Climate Conversations: Pathways to Action is a monthly webinar ...

NORMAL — A free festival honoring an esteemed American composer is coming to Illinois State University next month. The Charles Ives Sesquicentennial Festival is presenting free public lectures and ...

Complement activation may promote atherosclerosis. Yet, data on the to which extent complement, and more specifically the alternative complement pathway, is activated in patients with carotid ...

Harvard Medical School canceled a planned Jan. 21 lecture on wartime healthcare and a subsequent panel with patients from Gaza receiving care in Boston in response to objections that students would ...

Programmes which offer a pathway for admission to individuals in need of international protection through their identification and transfer from the first country of asylum to a third country where ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA ...